Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04670575 · ClinicalTrials.gov registry record
Vivity Outcomes in Patients With Early Stage Glaucoma
A clinical trial, sponsored by Vance Thompson Vision.
- Completed
- Registry status
- 27
- Enrollment target
NCT04670575: Completed study, sponsored by Vance Thompson Vision.
NCT04670575 is a clinical trial that has completed, run by Vance Thompson Vision. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04670575 has completed, sponsored by Vance Thompson Vision.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
The goal of the study is to determine the visual outcomes in patients with mild, pre-perimetric glaucoma who undergo cataract surgery with implantation of the Alcon Vivity Extended Range Intraocular Lens (IOL).
Interventions
- PROCEDURE Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2022-11-30 |
What the finished NCT04670575 record still lists
NCT04670575 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL is the first listed.
NCT04670575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04670575 about?
NCT04670575 is a clinical study titled "Vivity Outcomes in Patients With Early Stage Glaucoma". The goal of the study is to determine the visual outcomes in patients with mild, pre-perimetric glaucoma who undergo cataract surgery with implantation of the Alcon Vivity Extended Range Intraocular Lens (IOL).
What is the current status of trial NCT04670575?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2021-01-01. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT04670575?
The interventions under investigation include: Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL (PROCEDURE).
Who is sponsoring clinical trial NCT04670575?
This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI